

Asia Pacific Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity

<https://marketpublishers.com/r/AA22F16800E8EN.html>

Date: August 2020

Pages: 96

Price: US\$ 2,550.00 (Single User License)

ID: AA22F16800E8EN

Abstracts

Asia Pacific influenza treatment market will grow by 6.8% annually with a total addressable market cap of \$2,873.1 million over 2020-2030 owing to the rising incidences of influenza, growing awareness and need for new drugs and treatment amid COVID-19 pandemic.

Highlighted with 30 tables and 43 figures, this 96-page report “Asia Pacific Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific influenza treatment market in every aspect of the classification from perspectives of Product Type, Influenza Type, Administration Route, Distribution Channel, and Country.

Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Oseltamivir Phosphate

Baloxavir Marboxil

Peramivir

Zanamivir

Other Drugs

Based on Influenza Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Influenza A

Influenza B

Influenza C

Based on Administration Route, the Asia Pacific market is segmented into the following

sub-markets with annual revenue for 2019-2030 included in each section.

Oral Administration

Other Administration Routes

Based on Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Retail Pharmacy

Hospital Pharmacy

Clinics

Online Stores

Geographically, the following national/local markets are fully investigated:

Japan

China

South Korea

Australia

India

Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product Type, Administration Route, and Distribution Channel over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific influenza treatment market are assayed quantitatively and qualitatively through GMD's Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):

AstraZeneca Plc
BioCryst Pharmaceuticals Inc.
Biondvax
Daiichi Sankyo Company
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

- 1.1 Industry Definition and Research Scope
 - 1.1.1 Industry Definition
 - 1.1.2 Research Scope
- 1.2 Research Methodology
 - 1.2.1 Overview of Market Research Methodology
 - 1.2.2 Market Assumption
 - 1.2.3 Secondary Data
 - 1.2.4 Primary Data
 - 1.2.5 Data Filtration and Model Design
 - 1.2.6 Market Size/Share Estimation
 - 1.2.7 Research Limitations
- 1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

- 2.1 Market Size and Forecast
 - 2.1.1 Impact of COVID-19 on the Market
- 2.2 Major Growth Drivers
- 2.3 Market Restraints and Challenges
- 2.4 Emerging Opportunities and Market Trends
- 2.5 Porter's Fiver Forces Analysis

3 SEGMENTATION OF ASIA PACIFIC MARKET BY PRODUCT TYPE

- 3.1 Market Overview by Product Type
- 3.2 Oseltamivir Phosphate
- 3.3 Baloxavir Marboxil
- 3.4 Peramivir
- 3.5 Zanamivir
- 3.6 Other Drugs

4 SEGMENTATION OF ASIA PACIFIC MARKET BY INFLUENZA TYPE

- 4.1 Market Overview by Influenza Type
- 4.2 Influenza A

4.3 Influenza B

4.4 Influenza C

5 SEGMENTATION OF ASIA PACIFIC MARKET BY ADMINISTRATION ROUTE

5.1 Market Overview by Administration Route

5.2 Oral Administration

5.3 Other Administration Routes

6 SEGMENTATION OF ASIA PACIFIC MARKET BY DISTRIBUTION CHANNEL

6.1 Market Overview by Distribution Channel

6.2 Retail Pharmacy

6.3 Hospital Pharmacy

6.4 Clinics

6.5 Online Stores

7 ASIA-PACIFIC MARKET 2019-2030 BY COUNTRY

7.1 Overview of Asia-Pacific Market

7.2 Japan

7.3 China

7.4 Australia

7.5 India

7.6 South Korea

7.7 Rest of APAC Region

8 COMPETITIVE LANDSCAPE

8.1 Overview of Key Vendors

8.2 New Product Launch, Partnership, Investment, and M&A

8.3 Company Profiles

AstraZeneca Plc

BioCryst Pharmaceuticals Inc.

Biondavax

Daiichi Sankyo Company

F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)

GlaxoSmithKline Plc

Mylan N.V

Natco Pharma Limited
Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited

9 INVESTING IN ASIA PACIFIC MARKET: RISK ASSESSMENT AND MANAGEMENT

9.1 Risk Evaluation of Asia Pacific Market
9.2 Critical Success Factors (CSFs)
Related Reports and Products

List Of Tables

LIST OF TABLES

Table 1. Snapshot of Asia Pacific Influenza Treatment Market, 2019-2030

Table 2. Main Product Trends and Market Opportunities in Asia Pacific Influenza Treatment Market

Table 3. Asia Pacific Influenza Treatment Market by Product Type, 2019-2030, \$ mn

Table 4. Asia Pacific Influenza Treatment Market by Influenza Type, 2019-2030, \$ mn

Table 5. Asia Pacific Influenza Treatment Market by Administration Route, 2019-2030, \$ mn

Table 6. Asia Pacific Influenza Treatment Market by Distribution Channel, 2019-2030, \$ mn

Table 7. APAC Influenza Treatment Market by Country, 2019-2030, \$ mn

Table 8. Japan Influenza Treatment Market by Product Type, 2019-2030, \$ mn

Table 9. Japan Influenza Treatment Market by Administration Route, 2019-2030, \$ mn

Table 10. Japan Influenza Treatment Market by Distribution Channel, 2019-2030, \$ mn

Table 11. China Influenza Treatment Market by Product Type, 2019-2030, \$ mn

Table 12. China Influenza Treatment Market by Administration Route, 2019-2030, \$ mn

Table 13. China Influenza Treatment Market by Distribution Channel, 2019-2030, \$ mn

Table 14. Australia Influenza Treatment Market by Product Type, 2019-2030, \$ mn

Table 15. Australia Influenza Treatment Market by Administration Route, 2019-2030, \$ mn

Table 16. Australia Influenza Treatment Market by Distribution Channel, 2019-2030, \$ mn

Table 17. India Influenza Treatment Market by Product Type, 2019-2030, \$ mn

Table 18. India Influenza Treatment Market by Administration Route, 2019-2030, \$ mn

Table 19. India Influenza Treatment Market by Distribution Channel, 2019-2030, \$ mn

Table 20. South Korea Influenza Treatment Market by Product Type, 2019-2030, \$ mn

Table 21. South Korea Influenza Treatment Market by Administration Route, 2019-2030, \$ mn

Table 22. South Korea Influenza Treatment Market by Distribution Channel, 2019-2030, \$ mn

Table 23. Influenza Treatment Market in Rest of APAC by Country, 2019-2030, \$ mn

Table 24. AstraZeneca Plc: Company Snapshot

Table 25. AstraZeneca Plc: Business Segmentation

Table 26. AstraZeneca Plc: Product Portfolio

Table 27. AstraZeneca Plc: Revenue, 2016-2018, \$ mn

Table 28. AstraZeneca Plc: Recent Developments

Table 29. Risk Evaluation for Investing in Asia Pacific Market, 2019-2030

Table 30. Critical Success Factors and Key Takeaways

List Of Figures

LIST OF FIGURES

Figure 1. Research Method Flow Chart

Figure 2. Breakdown of Primary Research

Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation

Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030

Figure 5. Asia Pacific Influenza Treatment Market, 2019-2030, \$ mn

Figure 6. Impact of COVID-19 on Business

Figure 7. Primary Drivers and Impact Factors of Asia Pacific Influenza Treatment Market

Figure 8. GDP per capita in the World, 1960-2018, \$ thousand

Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million

Figure 10. Primary Restraints and Impact Factors of Asia Pacific Influenza Treatment Market

Figure 11. Investment Opportunity Analysis

Figure 12. Porter's Five Forces Analysis of Asia Pacific Influenza Treatment Market

Figure 13. Breakdown of Asia Pacific Influenza Treatment Market by Product Type, 2019-2030, % of Revenue

Figure 14. Asia Pacific Addressable Market Cap in 2020-2030 by Product Type, Value (\$ mn) and Share (%)

Figure 15. Asia Pacific Influenza Treatment Market: Oseltamivir Phosphate, 2019-2030, \$ mn

Figure 16. Asia Pacific Influenza Treatment Market: Baloxavir Marboxil, 2019-2030, \$ mn

Figure 17. Asia Pacific Influenza Treatment Market: Peramivir, 2019-2030, \$ mn

Figure 18. Asia Pacific Influenza Treatment Market: Zanamivir, 2019-2030, \$ mn

Figure 19. Asia Pacific Influenza Treatment Market: Other Drugs, 2019-2030, \$ mn

Figure 20. Breakdown of Asia Pacific Influenza Treatment Market by Influenza Type, 2019-2030, % of Sales Revenue

Figure 21. Asia Pacific Addressable Market Cap in 2020-2030 by Influenza Type, Value (\$ mn) and Share (%)

Figure 22. Asia Pacific Influenza Treatment Market: Influenza A, 2019-2030, \$ mn

Figure 23. Asia Pacific Influenza Treatment Market: Influenza B, 2019-2030, \$ mn

Figure 24. Asia Pacific Influenza Treatment Market: Influenza C, 2019-2030, \$ mn

Figure 25. Breakdown of Asia Pacific Influenza Treatment Market by Administration Route, 2019-2030, % of Sales Revenue

Figure 26. Asia Pacific Addressable Market Cap in 2020-2030 by Administration Route, Value (\$ mn) and Share (%)

Figure 27. Asia Pacific Influenza Treatment Market: Oral Administration, 2019-2030, \$ mn

Figure 28. Asia Pacific Influenza Treatment Market: Other Administration Routes, 2019-2030, \$ mn

Figure 29. Breakdown of Asia Pacific Influenza Treatment Market by Distribution Channel, 2019-2030, % of Revenue

Figure 30. Asia Pacific Addressable Market Cap in 2020-2030 by Distribution Channel, Value (\$ mn) and Share (%)

Figure 31. Asia Pacific Influenza Treatment Market: Retail Pharmacy, 2019-2030, \$ mn

Figure 32. Asia Pacific Influenza Treatment Market: Hospital Pharmacy, 2019-2030, \$ mn

Figure 33. Asia Pacific Influenza Treatment Market: Clinics, 2019-2030, \$ mn

Figure 34. Asia Pacific Influenza Treatment Market: Online Stores, 2019-2030, \$ mn

Figure 35. Breakdown of APAC Influenza Treatment Market by Country, 2019 and 2030, % of Revenue

Figure 36. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value (\$ mn) and Share (%)

Figure 37. Influenza Treatment Market in Japan, 2019-2030, \$ mn

Figure 38. Influenza Treatment Market in China, 2019-2030, \$ mn

Figure 39. Influenza Treatment Market in Australia, 2019-2030, \$ mn

Figure 40. Influenza Treatment Market in India, 2019-2030, \$ mn

Figure 41. Influenza Treatment Market in South Korea, 2019-2030, \$ mn

Figure 42. Influenza Treatment Market in Rest of APAC, 2019-2030, \$ mn

Figure 43. Growth Stage of Asia Pacific Influenza Treatment Industry over the Forecast Period

COMPANIES MENTIONED

AstraZeneca Plc

BioCryst Pharmaceuticals Inc.

Biondavax

Daiichi Sankyo Company

F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)

GlaxoSmithKline Plc

Mylan N.V

Natco Pharma Limited

Novartis AG
Sanofi
Seqirus
Teva Pharmaceutical Industries Limited

I would like to order

Product name: Asia Pacific Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity

Product link: <https://marketpublishers.com/r/AA22F16800E8EN.html>

Price: US\$ 2,550.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AA22F16800E8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970